|
|
 |
- Non-competing Continuations (Type 5s) - all RPG mechanisms
In accordance with NIH policy, NCI will pay non-competing continuation (Type 5) RPG grants at a level which will provide an average 1 percent increase for categorical (non-modular) awards. This is a 2 percent reduction from the committed level for categorical grants. Modular Type-5 grants will receive the committed level of support. Non-competing grants that were awarded under the earlier continuing resolution and reduced to 80% of the committed levels will be restored to match the new funding policy. Grants funded under non-RPG operating budgets may be subject to larger cuts as will be proposed by the appropriate extramural offices, centers, and divisions.
- Competing Budget Policy Statement
The NIH has established a funding policy for FY 2008 which intends to increase the average cost per grant approximately 1 percent over the competing average cost last year. To achieve that objective, competing new (Type-1) grants will be reduced approximately 17% from the level approved by peer review. Smaller grants (those with 7 modules or fewer) will be cut less than larger grants. Competing continuation (Type 2) grants will be awarded at approximately 3% above the current level of support. Competing grants that were awarded under the earlier continuing resolution will be restored to match this final operating funding policy.
- Competing New (Type 1) and Continuation (Type 2) R01s
Effective with the September 2007 National Cancer Advisory Board (NCAB) round (the first funding cycle of FY 2008), Type-1 and Type-2 R01 applications up to the 14.0 percentile will be paid. Non-percentiled R01s will be paid on a case by case basis.
R01s designated as new MERIT Awards will be permitted approximately 5% growth over current levels. MERIT extension requests will be paid at program recommended levels.
- Large Dollar Amount Percentiled R01s
For the first and second funding cycles of FY 2008, the payline for large percentiled R01 applications ($700,000 or more direct cost requested in any year) is the 14.0 percentile. The payline for the third funding cycle has not yet been established.
- Competing New (Type 1) R01 Applications from First-time R01 Investigators
NCI has a strong commitment to first-time R01 awardees. Therefore, applicants eligible for consideration as first-time R01 investigators in FY 2008 will be paid using an extended payline of the 19.0 percentile. The current definition of first-time R01 investigators can be found in the Application for a Public Health Service Grants (PHS-398): http://grants.nih.gov/grants/funding/phs398/phs398.pdf (PDF) - scroll to page 26 also known as 34 of 144.
- Program Project (P01) Applications (new and competing continuations)
P01s will continue to be paid on a case by case basis. P01 applicants will be notified of their potential for funding by the NCI program staff.
To achieve the budget policy objectives, competing new (Type-1) P01 grants will be reduced approximately 17% from the level approved by peer review, and competing continuation (Type 2) grants will be awarded at approximately 3% above the current level of support.
- Request for Applications (RFAs)
NCI is committed to the review and funding of RFAs that have been previously announced and solicited for competition and award in FY 2008. As always, success rates for RFAs will depend on the amount of funds available, the number of applications submitted, programmatic priority and the scientific merit of the applications received. Please consult the program director listed on your summary statement if you have questions.
To achieve the budget policy objectives, competing RFAs will comply with the budget policies established for R01 and P01 grants.
- Amended Applications (all mechanisms)
Amended applications submitted for the February/March, 2008 receipt date, will be considered for funding under FY 2009 budget plans, which are not yet known and may be different from these FY 2008 announced levels.
|
|
